Calendario›INCY›itacitinib

itacitinib

A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

Ensayo de INCYTE CORP en Myelofibrosis · Postlung Transplant (Bronchiolitis Obliterans) · Chronic Graft Versus Host Disease (del registro, en inglés).

Más ensayos de: Mielofibrosis.

Fase

Fase 2

Estado

Interrumpido

Participantes

18

previstos

Centros

21

Fin del objetivo primario

may 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en mar 2021.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «The decision to close the study was made due to the expiration of remaining drug supply.».

Qué mide

Treatment Emergent Adverse Events (TEAE's) (del registro, en inglés) (3 años)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a mutli-center open-label study to provide continued supply of itacitinib to participants from the following Incyte-sponsored studies of itacitinib: INCB39110-209, INCB39110-213, INCB39110-214, INCB39110-230, and 39110-309. Eligible participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. The original study is referred to as the "parent protocol". Participants who receive itacitinib in this study may continue treatment as long as the regimen is tolerated, the participant is deriving clinical benefit (in the opinion of the investigator), and the participant does not meet discontinuation criteria.

Más ensayos de INCY

Todos los de INCY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04640025), actualizada en jun 2026.